Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy.

To assess vitreous vascular endothelial growth factor (VEGF) concentrations in proliferative diabetic retinopathy (PDR) in comparison to proliferative vitreoretinopathy (PVR). Vitreous samples were collected from 69 eyes of 69 patients with traumatic lens dislocation (n = 10), grade B PVR with rhegmatogenous retinal detachment (n = 13), grade C PVR with rhegmatogenous retinal detachment (n = 14), PDR with vitreous hemorrhage (n = 18), and PDR with vitreous hemorrhage and tractional retinal detachment (n = 14). Vitreous fluid samples were obtained at vitrectomy, and the levels of VEGF were measured by enzyme-linked immunosorbent assay. The mean vitreous level of VEGF was 15.14 ± 5.22 pg/ml in eyes with grade B PVR, 99.15 ± 38.58 pg/ml in eyes with grade C PVR, 4,534.01 ± 1,193.28 pg/ml in eyes with vitreous hemorrhage secondary to PDR, 5,157.29 ± 969.44 pg/ml in eyes with vitreous hemorrhage and tractional retinal detachment secondary to PDR, and 16.19 ± 5.76 pg/ml in eyes of the control group with traumatic lens dislocation. Vitreous VEGF concentrations were significantly higher in the patients with grade C PVR, PDR with vitreous hemorrhage and PDR with vitreous hemorrhage and tractional retinal detachment in comparison to the control patients (p < 0.05). A significant alteration was not observed in patients with grade B PVR (p = 0.55). Vitreous VEGF concentrations are increased in PDR and grade C PVR. The high VEGF concentrations could suggest a possible effect of VEGF on advanced PVR.

Citirik M ，Kabatas EU ，Batman C ，Akin KO ，Kabatas N ... -  《-》

Upregulation of RAGE and its ligands in proliferative retinal disease.

Pachydaki SI ，Tari SR ，Lee SE ，Ma W ，Tseng JJ ，Sosunov AA ，Cataldergirmen G ，Scarmeas N ，Caspersen C ，Chang S ，Schiff WM ，Schmidt AM ，Barile GR ... -  《EXPERIMENTAL EYE RESEARCH》

Soluble TNF receptors in vitreoretinal proliferative disease.

Limb GA ，Hollifield RD ，Webster L ，Charteris DG ，Chignell AH ... -  《INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE》

Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy.

Abu El-Asrar AM ，Struyf S ，Kangave D ，Geboes K ，Van Damme J ... -  《EUROPEAN CYTOKINE NETWORK》

Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy.

Neovascular glaucoma is a frequent complication of vitrectomy performed to treat proliferative diabetic retinopathy (PDR). We assessed the level of vascular endothelial growth factor (VEGF) in the vitreous fluid obtained during vitrectomy and at postoperative fluid-air exchange. We measured VEGF levels in vitreous samples from 17 eyes of 15 patients with PDR during vitrectomy and fluid samples obtained during fluid-air exchange 5 to 36 days postoperatively. Six of the 17 eyes had iris neovascularization after vitrectomy. Vascular endothelial growth factor levels also were measured in the vitreous fluid obtained from 8 eyes with a macular hole during vitrectomy and postoperative fluid-air exchange. We measured the plasma VEGF levels in all patients. The mean VEGF levels in 17 eyes with PDR were 1162.3+/-173.2 pg/ml in the vitreous samples and 1180.4+/-182.8 pg/ml in the postoperative fluid samples. The mean plasma VEGF level was 116.1+/-10.2 pg/ml in eyes with PDR, and the mean plasma VEGF level was 118.5+/-15.2 pg/ml in patients with a macular hole. The mean VEGF levels were 96.9+/-11.5 pg/ml in the vitreous samples and 73.9+/-12.3 pg/ml in the fluid samples in eyes with a macular hole. A high VEGF level was maintained in the vitreous cavity after vitrectomy for PDR. The VEGF level in eyes with PDR was 10 times higher than that in the plasma. The results suggest that there is persistent secretion of VEGF into the vitreous cavity even after vitrectomy for PDR.

Itakura H ，Kishi S ，Kotajima N ，Murakami M ... -  《-》